Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD

0.8838  -0.01 (-1.47%)

After market: 0.87 -0.01 (-1.56%)

Fundamental Rating

2

Taking everything into account, XLO scores 2 out of 10 in our fundamental rating. XLO was compared to 561 industry peers in the Biotechnology industry. XLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XLO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XLO had negative earnings in the past year.
XLO had a negative operating cash flow in the past year.
In the past 5 years XLO always reported negative net income.
XLO had a negative operating cash flow in each of the past 5 years.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of XLO (-81.94%) is worse than 70.23% of its industry peers.
XLO's Return On Equity of -330.95% is on the low side compared to the rest of the industry. XLO is outperformed by 74.33% of its industry peers.
Industry RankSector Rank
ROA -81.94%
ROE -330.95%
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

XLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XLO has more shares outstanding
XLO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -9.16, we must say that XLO is in the distress zone and has some risk of bankruptcy.
XLO has a worse Altman-Z score (-9.16) than 72.55% of its industry peers.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.16
ROIC/WACCN/A
WACC9.92%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

XLO has a Current Ratio of 2.21. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.21, XLO is doing worse than 73.44% of the companies in the same industry.
A Quick Ratio of 2.21 indicates that XLO has no problem at all paying its short term obligations.
XLO has a Quick ratio of 2.21. This is in the lower half of the industry: XLO underperforms 71.12% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.32% over the past year.
EPS 1Y (TTM)67.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

XLO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.00% yearly.
Based on estimates for the next years, XLO will show a very strong growth in Revenue. The Revenue will grow by 53.85% on average per year.
EPS Next Y51.87%
EPS Next 2Y16.99%
EPS Next 3Y0.45%
EPS Next 5Y18%
Revenue Next Year225.93%
Revenue Next 2Y82.33%
Revenue Next 3Y49.24%
Revenue Next 5Y53.85%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.99%
EPS Next 3Y0.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XLO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XILIO THERAPEUTICS INC

NASDAQ:XLO (5/23/2025, 9:04:39 PM)

After market: 0.87 -0.01 (-1.56%)

0.8838

-0.01 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners50.22%
Inst Owner Change-9.15%
Ins Owners0.55%
Ins Owner Change13.55%
Market Cap45.76M
Analysts80
Price Target4.08 (361.64%)
Short Float %0.94%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.15%
Min EPS beat(2)8.61%
Max EPS beat(2)11.7%
EPS beat(4)2
Avg EPS beat(4)-110.27%
Min EPS beat(4)-458.06%
Max EPS beat(4)11.7%
EPS beat(8)6
Avg EPS beat(8)-48.44%
EPS beat(12)8
Avg EPS beat(12)-30.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-40.19%
Min Revenue beat(2)-48.27%
Max Revenue beat(2)-32.1%
Revenue beat(4)0
Avg Revenue beat(4)-68.15%
Min Revenue beat(4)-100%
Max Revenue beat(4)-32.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)612.68%
EPS NY rev (1m)-64.42%
EPS NY rev (3m)-70.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)51.72%
Revenue NY rev (1m)-48.03%
Revenue NY rev (3m)-30.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.21
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 2.6
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.12
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.94%
ROE -330.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.19%
Cap/Sales 0.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -9.16
F-Score5
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.97%
EPS Next Y51.87%
EPS Next 2Y16.99%
EPS Next 3Y0.45%
EPS Next 5Y18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year225.93%
Revenue Next 2Y82.33%
Revenue Next 3Y49.24%
Revenue Next 5Y53.85%
EBIT growth 1Y24.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y73.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.22%
OCF growth 3YN/A
OCF growth 5YN/A